Carrick Therapeutics and Menarini announce Clinical Trial collaboration to evaluate Samuraciclib and Elacestrant combination against HR+, HER2- breast cancer
![Immagine News](/media/l4el5htd/cat-2.jpg?anchor=center&mode=crop&width=722&height=442)
Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, and the Menarini Group ("Menarini"), announced a clinical trial collaboration and supply agreement.
This agreement covers the execution of a Phase 2 clinical trial to evaluate the novel combination of Carrick’s samuraciclib (CT7001), an oral and first-in-class inhibitor of CDK7, and Menarini‘s oral selective estrogen receptor degrader (SERD), elacestrant, in patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer. Menarini and Carrick will jointly sponsor the clinical trial.
Carrick anticipates initiating the Phase 2 clinical trial in 2023.
This new study will expand Carrick’s portfolio of ongoing clinical trials with samuraciclib. The company presented encouraging results from a clinical study combining samuraciclib with fulvestrant at the 2021 San Antonio Breast Cancer Symposium.